Skip to content
  • origimm
  • Skin Microbiome
  • Indications
    • Acne Vulgaris
    • Background
    • Solution
    • Implant-Associated Infections
    • Background
    • Solution
  • For Partners
  • For Patients
    • Acne Patients
    • Our motivation
    • Answers to frequent questions
  • About us
    • Company
    • Our vision
    • Management board
    • News
    • Join us
    • Open positions
    • Stakeholders
  • Contact
    • Contact
    • Location

Successful closing of Series A financing round

Posted on September 29, 2016February 21, 2019 by Origimm Biotechnology in Corporate News

Winning project of 2016 StartTech grant competition
Prophylactic therapy against S. epidermidis implant-associated infections

Post navigation

Previous Post ORIGIMM RECEIVES GRANT FROM THE AUSTRIAN RESEARCH PROMOTION AGENCY (FFG) FOR DEVELOPMENT OF ITS P. ACNES VACCINE, DECEMBER 2015, VIENNA
Next Post Conferences attended in 2016
  • Home
  • Skin Microbiome
  • Indications
  • For Partners
  • For Patients
  • About us
  • Contact
  • Legal notice
  • Data privacy statement
protected by Google reCAPTCHA - Privacy Policy - Terms of Use // Webdesign: mausblau.at
By continuing to browse the site you are agreeing to our use of cookies. More about cookies and the protection of your data: Data privacy statement